Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female recipients of single or double renal transplant performed since at least one year and no more that 5 years~* Age \> 18 yrs~* Adequate and stable renal function~* Informed consent.~Exclusion criteria:~* Kidney transplant combined with other organs;~* Significant proteinuria~* Severe ongoing infections;~* Present or historical malignant neoplasia, of any type, with the exception of excised non metastatic non-melanoma skin cancer and previous malignant neoplasia cured since at least 5 years;~* Relapse of the end-stage renal disease on the transplanted kidney;~* Leucopenia, thrombocytopenia or severe anemia;~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Full Dose Myfortic® and Reduced Dose Neoral® (Type: EXPERIMENTAL): The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
- Standard Dose of Myfortic® and Standard Dose of CsA-ME (Type: ACTIVE_COMPARATOR): Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.

Based on this trial design, predict the completion outcome and termination type (if applicable).